ABL Diagnostics Advances Platform-Agnostic NGS Strategy Through DeepChek® Verification on Element Biosciences’ AVITI™
Ongoing verification study supports compatibility of DeepChek® with the AVITI™ platform. Expands opportunities in infectious disease sequencing workflows. WOIPPY, FRANCE, June 9, 2026 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), a …